Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

2.

Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.

Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA, Fu XY.

Nature. 1997 Mar 20;386(6622):288-92.

PMID:
9069288
3.

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.

Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ.

Oncogene. 2000 Jul 6;19(29):3309-20.

4.

The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling.

Lievens PM, Mutinelli C, Baynes D, Liboi E.

J Biol Chem. 2004 Oct 8;279(41):43254-60. Epub 2004 Aug 2.

5.

Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.

Lievens PM, De Servi B, Garofalo S, Lunstrum GP, Horton WA, Liboi E.

Int J Biochem Cell Biol. 2008;40(11):2649-59. doi: 10.1016/j.biocel.2008.05.017. Epub 2008 Jun 5.

PMID:
18577465
6.

Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.

Harada D, Yamanaka Y, Ueda K, Nishimura R, Morishima T, Seino Y, Tanaka H.

Bone. 2007 Aug;41(2):273-81. Epub 2007 Feb 9.

PMID:
17561467
7.

Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum.

Lievens PM, Zanolli E, Garofalo S, Liboi E.

FEBS Lett. 2009 Oct 6;583(19):3254-8. doi: 10.1016/j.febslet.2009.09.021. Epub 2009 Sep 15.

10.

Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.

Iwata T, Li CL, Deng CX, Francomano CA.

Hum Mol Genet. 2001 Jun 1;10(12):1255-64.

PMID:
11406607
11.
12.

A central nervous system specific mouse model for thanatophoric dysplasia type II.

Lin T, Sandusky SB, Xue H, Fishbein KW, Spencer RG, Rao MS, Francomano CA.

Hum Mol Genet. 2003 Nov 1;12(21):2863-71. Epub 2003 Sep 9.

PMID:
12966031
13.

Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.

Chen J, Williams IR, Lee BH, Duclos N, Huntly BJ, Donoghue DJ, Gilliland DG.

Blood. 2005 Jul 1;106(1):328-37. Epub 2005 Mar 22.

15.
16.

A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.

Jin M, Yu Y, Qi H, Xie Y, Su N, Wang X, Tan Q, Luo F, Zhu Y, Wang Q, Du X, Xian CJ, Liu P, Huang H, Shen Y, Deng CX, Chen D, Chen L.

Hum Mol Genet. 2012 Dec 15;21(26):5443-55. doi: 10.1093/hmg/dds390. Epub 2012 Sep 26.

17.
18.

Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Meyer AN, McAndrew CW, Donoghue DJ.

Cancer Res. 2008 Sep 15;68(18):7362-70. doi: 10.1158/0008-5472.CAN-08-0575.

19.
20.

K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways.

Lievens PM, Roncador A, Liboi E.

J Mol Biol. 2006 Mar 31;357(3):783-92. Epub 2006 Feb 3.

PMID:
16476447

Supplemental Content

Support Center